UNSPSC 51281504: Pyrazinamide

This classification denotes an antitubercular agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2KNI5N06TI. European Medicines Agency schedules Pyrazinamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10163MIG. Pyrazinamide generally arises in the molecular formula C5H5N3O.

The term PYRAZINAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, no. 3 1962, list 4.) PYRAZINAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pyrazinamide under HS 29339990 and SITC 51577. As of Q4 2014, PYRAZINAMIDE remains the US FDA Preferred Term for this commodity. Pyrazinamide bears US NLM identifiers UMLS ID C0034239 and NCI Concept Code C29395. SMILES: O=C(N)C1NCCNC1.

UNSPSC 51281504 Pyrazinamide is a Commodity code that covers pharmaceutical procurement by state and local health agencies, though recent activity shows limited direct solicitation for pyrazinamide itself. Instead, state and local governments use this code tier to acquire a broader range of pharmaceutical products and medical supplies—antibiotics, antimicrobial agents, naloxone, and associated medical devices—typically through piggyback agreements with established pharmaceutical consortiums and competitive bidding processes. The Illinois Department of Public Health and Seminole County, Florida represent the kinds of issuing bodies active under this code: state health departments and county health or emergency management agencies that procure pharmaceuticals to support public health, disease prevention, and community health initiatives. These purchases are commonly structured as multi-year contracts with quarterly or periodic deliveries and often include compliance requirements such as drug-free workplace certification, E-Verify verification, and insurance coverage mandates.

Recent activity centers in Illinois and Florida. The Illinois Department of Public Health awarded a pharmaceutical piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026, for antibiotic supply (Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets) totaling $2,999,999.11 over three years via an Invitation for Bid (IFB) process. Seminole County, Florida issued an IFB (number IFB60459723LAS) on June 30, 2026, to procure 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, initial two-year term, and one-year renewal option; this procurement was potentially FEMA-funded and required full shipping and delivery cost inclusion in vendor proposals.